Marshall Wace LLP Reduces Holdings in Ultralife Co. (NASDAQ:ULBI)

Marshall Wace LLP decreased its stake in shares of Ultralife Co. (NASDAQ:ULBI) by 13.4% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 37,983 shares of the technology company’s stock after selling 5,864 shares during the period. Marshall Wace LLP owned approximately 0.23% of Ultralife worth $403,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of ULBI. Dimensional Fund Advisors LP boosted its position in Ultralife by 5.3% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,024,491 shares of the technology company’s stock valued at $10,880,000 after acquiring an additional 51,399 shares in the last quarter. Vanguard Group Inc. grew its stake in Ultralife by 1.3% in the first quarter. Vanguard Group Inc. now owns 515,840 shares of the technology company’s stock worth $4,545,000 after purchasing an additional 6,640 shares during the period. Janney Montgomery Scott LLC raised its holdings in Ultralife by 10.0% in the first quarter. Janney Montgomery Scott LLC now owns 439,100 shares of the technology company’s stock worth $3,868,000 after purchasing an additional 40,000 shares in the last quarter. Renaissance Technologies LLC lifted its position in Ultralife by 9.1% during the second quarter. Renaissance Technologies LLC now owns 242,490 shares of the technology company’s stock valued at $2,575,000 after buying an additional 20,300 shares during the period. Finally, Acadian Asset Management LLC boosted its holdings in shares of Ultralife by 4.4% during the 2nd quarter. Acadian Asset Management LLC now owns 146,635 shares of the technology company’s stock valued at $1,556,000 after buying an additional 6,206 shares in the last quarter. Hedge funds and other institutional investors own 30.68% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently issued reports on the stock. Benchmark lifted their price target on shares of Ultralife from $13.00 to $14.00 and gave the company a “buy” rating in a research report on Thursday, June 27th. StockNews.com lowered shares of Ultralife from a “strong-buy” rating to a “buy” rating in a report on Thursday, October 3rd.

Ultralife Trading Down 2.0 %

NASDAQ ULBI opened at $8.96 on Friday. Ultralife Co. has a 12 month low of $6.36 and a 12 month high of $13.39. The company has a current ratio of 4.07, a quick ratio of 2.06 and a debt-to-equity ratio of 0.07. The stock’s fifty day moving average price is $9.83 and its 200-day moving average price is $10.37. The stock has a market cap of $148.92 million, a P/E ratio of 14.00 and a beta of 0.97.

Ultralife (NASDAQ:ULBI) last announced its quarterly earnings data on Thursday, July 25th. The technology company reported $0.22 EPS for the quarter, beating the consensus estimate of $0.14 by $0.08. The company had revenue of $42.98 million for the quarter. Ultralife had a net margin of 5.96% and a return on equity of 9.32%.

Ultralife Profile

Ultralife Corporation, together with its subsidiaries, designs, manufactures, installs, and maintains power, and communication and electronics systems worldwide. The company operates in two segments, Battery & Energy Products and Communications Systems. The Battery & Energy Products segment offers lithium 9-volt, cylindrical, thin lithium manganese dioxide, rechargeable, and other non-rechargeable batteries; lithium-ion cells, multi-kilowatt module lithium-ion battery systems, and uninterruptable power supplies; and rugged military and commercial battery charging systems and accessories, including smart chargers, multi-bay charging systems, and various cables.